Pramipexole Accord

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

pramipeksol dihidroklorid monohidrat

Available from:

Accord Healthcare S.L.U.

ATC code:

N04BC05

INN (International Name):

pramipexole

Therapeutic group:

Anti-parkinsonska zdravila

Therapeutic area:

Parkinson Disease; Restless Legs Syndrome

Therapeutic indications:

Zdravilo Pramipeksol Accord je indicirano pri odraslih za zdravljenje znakov in simptomov idiopatske Parkinsonove bolezni, samega (brez levodope) ali v kombinaciji z levodopo, i. v času bolezni, do poznih stopenj, ko se učinek levodope izčrpa ali postane neskladen, pojavijo pa se tudi nihanja terapevtskega učinka (nihanja na koncu odmerka ali "on-off" nihanja).

Product summary:

Revision: 10

Authorization status:

Pooblaščeni

Authorization date:

2011-09-29

Patient Information leaflet

                                22
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
Neuporabljena zdravila ali odpadne snovi se morajo odstraniti v skladu
z lokalnimi predpisi.
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Accord Healthcare S.L.U.
World Trade Center, Moll de Barcelona, s/n,
Edifici Est 6ª planta,
08039 Barcelona,
Španija
12.
ŠTEVILKA(E) DOVOLJENJA(DOVOLJENJ) ZA PROMET
EU/1/11/728/001-002 (30/100 tablet v alu / alu blister)
13.
IZDELOVALČEVA ŠTEVILKA SERIJE IZDELAVE ZDRAVILA
Serija {številka}
14.
NAČIN IZDAJANJA ZDRAVILA
Izdaja zdravila je le na recept.
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Pramipeksol Accord 0,088 mg
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA
_ _
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI
_ _
PC:
SN:
NN:
Zdravilo nima veā dovoljenja za promet
23
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI
DVOJNEM TRAKU
PRETISNI OMOT ALUMINIJ-ALUMINIJ
1.
IME ZDRAVILA
Pramipeksol Accord 0,088 mg tablete
Pramipeksol
2.
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Accord (Logo)
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
4.
ŠTEVILKA SERIJE
Lot
5.
DRUGI PODATKI
Zdravilo nima veā dovoljenja za promet
24
PODATKI NA ZUNANJI OVOJNINI IN PRIMARNI OVOJNINI
ŠKATLA ZA PRETISNE OMOTE
1.
IME ZDRAVILA
Pramipeksol Accord 0,18 mg tablete
Pramipeksol
2.
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN
Ena tableta vsebuje 0,25 mg pramipeksola v obliki 0,18 mg
pramipeksolijevega diklorida
monohidrata.
3.
SEZNAM POMOŽNIH SNOVI
4.
FARMACEVTSKA OBLIKA IN VSEBINA
30 tablet
100 tablet
5.
POSTOPEK IN POT(I) UPORABE ZDRAVILA
Pred uporabo preberite priloženo besedilo.
Peroralna uporaba
6.
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN
POGLEDA OTROK
Zdravilo shranjujte nedosegljivo otrokom!
7.
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA
8.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
Shranjujte na temperaturi po
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
Zdravilo nima veā dovoljenja za promet
2
1.
IME ZDRAVILA
Pramipeksol Accord 0,088 mg tablete
Pramipeksol Accord 0,18 mg tablete
Pramipeksol Accord 0,35 mg tablete
Pramipeksol Accord 0,7 mg tablete
Pramipeksol Accord 1,1 mg tablete
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Pramipeksol Accord 0,088 mg tablete
Ena tableta vsebuje 0,088 mg pramipeksola v obliki 0,125 mg
pramipeksolijevega diklorida
monohidrata.
Pramipeksol Accord 0,18 mg tablete
Ena tableta vsebuje 0,18 mg pramipeksola v obliki 0,25 mg
pramipeksolijevega diklorida
monohidrata.
Pramipeksol Accord 0,35 mg tablete
Ena tableta vsebuje 0,35 mg pramipeksola v obliki 0,5 mg
pramipeksolijevega diklorida monohidrata.
Pramipeksol Accord 0,7 mg tablete
Ena tableta vsebuje 0,7 mg pramipeksola v obliki 1,0 mg
pramipeksolijevega diklorida monohidrata.
Pramipeksol Accord 1,1 mg tablete
Ena tableta vsebuje 1,1 mg pramipeksola v obliki 1,5 mg
pramipeksolijevega diklorida monohidrata.
_ _
_Opomba: _
Odmerki pramipeksola, kot jih navajajo v literaturi, se nanašajo na
sol. Zato so tu odmerki izraženi za
obe obliki, za pramipeksol in pramipeksolijevo sol (v oklepaju).
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
Tableta.
Pramipeksol Accord 0,088 mg tablete
Tablete so bele ali sivo bele, okrogle, sploščene s poševnim robom,
z delilno zarezo na obeh straneh,
vtisnjeno oznako ‘I1’ na eni in brez oznake na drugi strani.
Pramipeksol Accord 0,18 mg tablete
Tablete so bele ali sivo bele, okrogle, sploščene s poševnim robom
in razdelilno zarezo na obeh
straneh in vtisnjeno oznako ‘I’ in ‘2’ na eni strani.
Tablete lahko razdelimo na enaki polovici.
Pramipeksol Accord 0,35 mg tablete
Tablete so bele ali sivo bele, okrogle, sploščene s poševnim robom
in razdelilno zarezo na obeh
straneh in vtisnjeno oznako ‘I’ in ‘3’ na eni strani.
Tablete lahko razdelimo na enaki polovici.
Pramipeksol Accord 0,7 mg tablete
Zdravilo nima veā dovoljenja za promet
3
Tablete so bele ali sivo
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 11-03-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 11-03-2024
Public Assessment Report Public Assessment Report Bulgarian 27-09-2016
Patient Information leaflet Patient Information leaflet Spanish 11-03-2024
Public Assessment Report Public Assessment Report Spanish 27-09-2016
Patient Information leaflet Patient Information leaflet Czech 11-03-2024
Public Assessment Report Public Assessment Report Czech 27-09-2016
Patient Information leaflet Patient Information leaflet Danish 11-03-2024
Public Assessment Report Public Assessment Report Danish 27-09-2016
Patient Information leaflet Patient Information leaflet German 11-03-2024
Public Assessment Report Public Assessment Report German 27-09-2016
Patient Information leaflet Patient Information leaflet Estonian 11-03-2024
Public Assessment Report Public Assessment Report Estonian 27-09-2016
Patient Information leaflet Patient Information leaflet Greek 11-03-2024
Public Assessment Report Public Assessment Report Greek 27-09-2016
Patient Information leaflet Patient Information leaflet English 11-03-2024
Public Assessment Report Public Assessment Report English 27-09-2016
Patient Information leaflet Patient Information leaflet French 11-03-2024
Public Assessment Report Public Assessment Report French 27-09-2016
Patient Information leaflet Patient Information leaflet Italian 11-03-2024
Public Assessment Report Public Assessment Report Italian 27-09-2016
Patient Information leaflet Patient Information leaflet Latvian 11-03-2024
Public Assessment Report Public Assessment Report Latvian 27-09-2016
Patient Information leaflet Patient Information leaflet Lithuanian 11-03-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 11-03-2024
Public Assessment Report Public Assessment Report Lithuanian 27-09-2016
Patient Information leaflet Patient Information leaflet Hungarian 11-03-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 11-03-2024
Public Assessment Report Public Assessment Report Hungarian 27-09-2016
Patient Information leaflet Patient Information leaflet Maltese 11-03-2024
Public Assessment Report Public Assessment Report Maltese 27-09-2016
Patient Information leaflet Patient Information leaflet Dutch 11-03-2024
Public Assessment Report Public Assessment Report Dutch 27-09-2016
Patient Information leaflet Patient Information leaflet Polish 11-03-2024
Public Assessment Report Public Assessment Report Polish 27-09-2016
Patient Information leaflet Patient Information leaflet Portuguese 11-03-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 11-03-2024
Public Assessment Report Public Assessment Report Portuguese 27-09-2016
Patient Information leaflet Patient Information leaflet Romanian 11-03-2024
Public Assessment Report Public Assessment Report Romanian 27-09-2016
Patient Information leaflet Patient Information leaflet Slovak 11-03-2024
Public Assessment Report Public Assessment Report Slovak 27-09-2016
Patient Information leaflet Patient Information leaflet Finnish 11-03-2024
Public Assessment Report Public Assessment Report Finnish 27-09-2016
Patient Information leaflet Patient Information leaflet Swedish 11-03-2024
Public Assessment Report Public Assessment Report Swedish 27-09-2016
Patient Information leaflet Patient Information leaflet Norwegian 11-03-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 11-03-2024
Patient Information leaflet Patient Information leaflet Icelandic 11-03-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 11-03-2024
Patient Information leaflet Patient Information leaflet Croatian 11-03-2024
Public Assessment Report Public Assessment Report Croatian 27-09-2016